Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERIFY: Vandetanib in Differentiated Thyroid Cancer
NCT01876784Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2013
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of vandetanib in differentiated thyroid cancer (DTC), sponsored by Sanofi. Started Sep 2013; status: completed.
02
Drugs
vandetanib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT01876784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01876784.